FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. What is described is a pharmaceutical composition used for treating and/or preventing pathological bone metabolism and containing this antibody. The invention can be used in medicine.
EFFECT: antibody and its functional fragment specifically recognising human Siglec-15 and possessing the osteoclast inhibitory activity are described.
73 cl, 57 dwg, 4 tbl, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2590711C2 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2644678C1 |
| HUMANISED ANTI-AXL ANTIBODIES | 2010 |
|
RU2571224C2 |
| ANTIBODY DIRECTED ON SIGLEC-15 PROTEIN, BOUND WITH OSTEOCLASTS | 2008 |
|
RU2475499C2 |
| ANTIBODY TO EPHA2 | 2008 |
|
RU2525133C2 |
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
| ANTI-GARP ANTIBODY | 2016 |
|
RU2769379C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2705367C2 |
